Akebia Therapeutics, Inc.AKBA
Market cap
$438.6M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | - | - | 0 | 1 | 1 | 2 | 2 | 2 | 2 | - | - |
| Stock-based compensation | 6 | 5 | 6 | 9 | 19 | 12 | 24 | 23 | 18 | 9 | 8 |
| Cash from operations | -27 | -52 | 58 | -56 | -97 | -257 | -110 | -253 | -73 | -23 | -41 |
| Capital expenditures | -0 | -0 | -3 | -2 | -2 | -7 | -0 | -0 | -0 | - | -0 |
| Cash from investing | -65 | -14 | 13 | -177 | 37 | 211 | -40 | 40 | -0 | - | -0 |
| Repurchases of common stock | 0 | - | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | - | - | - | 78 | 20 | - | - | - | - |
| Cash from financing | 104 | 83 | 67 | 116 | 97 | 89 | 232 | 134 | 15 | -25 | 50 |
| Free cash flow | - | ||||||||||
| FCF margin (%) | - | - | - | - | - |